Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population-based cohort of 500 patients with Gaucher disease in Israel.
Jaffe DH, Flaks-Manov N, Benis A, Gabay H, DiBonaventura M, Rosenbaum H, Joseph A, Bachrach A, Leventer-Roberts M. Jaffe DH, et al. Among authors: rosenbaum h. BMJ Open. 2019 Jan 21;9(1):e024251. doi: 10.1136/bmjopen-2018-024251. BMJ Open. 2019. PMID: 30670517 Free PMC article.
The role of high density lipoprotein in Type 1 Gaucher disease.
Watad S, Abu-Saleh N, Yousif A, Agbaria A, Rosenbaum H. Watad S, et al. Among authors: rosenbaum h. Blood Cells Mol Dis. 2018 Feb;68:43-46. doi: 10.1016/j.bcmd.2016.11.005. Epub 2016 Nov 12. Blood Cells Mol Dis. 2018. PMID: 27876360
Rethinking fatigue in Gaucher disease.
Zion YC, Pappadopulos E, Wajnrajch M, Rosenbaum H. Zion YC, et al. Among authors: rosenbaum h. Orphanet J Rare Dis. 2016 Apr 29;11(1):53. doi: 10.1186/s13023-016-0435-x. Orphanet J Rare Dis. 2016. PMID: 27129405 Free PMC article. Review.
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.
Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM. Biegstraaten M, et al. Among authors: rosenbaum h. Blood Cells Mol Dis. 2018 Feb;68:203-208. doi: 10.1016/j.bcmd.2016.10.008. Epub 2016 Oct 24. Blood Cells Mol Dis. 2018. PMID: 28274788 Free article.
Cholelithiasis in patients with Gaucher disease.
Rosenbaum H, Sidransky E. Rosenbaum H, et al. Blood Cells Mol Dis. 2002 Jan-Feb;28(1):21-7. doi: 10.1006/bcmd.2001.0480. Blood Cells Mol Dis. 2002. PMID: 11987238
The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease.
Drelichman G, Castañeda-Hernández G, Cem Ar M, Dragosky M, Garcia R, Lee H, Moiseev S, Naderi M, Rosenbaum H, Žnidar I, Zuluaga AF, Freisens S, Mistry PK. Drelichman G, et al. Among authors: rosenbaum h. Am J Hematol. 2020 Mar;95(3):233-237. doi: 10.1002/ajh.25701. Epub 2019 Dec 23. Am J Hematol. 2020. PMID: 31816110 Free PMC article. Review. No abstract available.
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A. Pastores GM, et al. Among authors: rosenbaum h. Blood Cells Mol Dis. 2014 Dec;53(4):253-60. doi: 10.1016/j.bcmd.2014.05.004. Epub 2014 Jun 18. Blood Cells Mol Dis. 2014. PMID: 24950666 Clinical Trial.
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Zimran A, Durán G, Mehta A, Giraldo P, Rosenbaum H, Giona F, Amato DJ, Petakov M, Muñoz ET, Solorio-Meza SE, Cooper PA, Varughese S, Chertkoff R, Brill-Almon E. Zimran A, et al. Among authors: rosenbaum h. Am J Hematol. 2016 Jul;91(7):656-60. doi: 10.1002/ajh.24369. Epub 2016 Apr 24. Am J Hematol. 2016. PMID: 27174694 Free PMC article. Clinical Trial.
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R. Zimran A, et al. Among authors: rosenbaum h. Blood Cells Mol Dis. 2019 Sep;78:14-21. doi: 10.1016/j.bcmd.2016.07.002. Epub 2016 Jul 18. Blood Cells Mol Dis. 2019. PMID: 27499018 Free article.
242 results